Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

BACKGROUND: In patients with Philadelphia-positive acute lymphoblastic leukemia, resistance to treatment with tyrosine kinase inhibitors is frequent and most often associated with the development of point mutations in the BCR-ABL kinase domain. We aimed to assess: (i) in how many patients BCR-ABL ki...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Soverini, Simona, Vitale, Antonella, Poerio, Angela, Gnani, Alessandra, Colarossi, Sabrina, Iacobucci, Ilaria, Cimino, Giuseppe, Elia, Loredana, Lonetti, Annalisa, Vignetti, Marco, Paolini, Stefania, Meloni, Giovanna, di Maio, Valeria, Papayannidis, Cristina, Amabile, Marilina, Guarini, Anna, Baccarani, Michele, Martinelli, Giovanni, Foà, Robin
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2011
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3069232/
https://ncbi.nlm.nih.gov/pubmed/21193419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.034173
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki